Serina Therapeutics Announces President and CEO will Speak at the Upcoming BIO CEO and Investor Conference in New York February 13-14th 2017

Huntsville, AL, January 4th, 2016

Serina Therapeutics, Inc., a clinical stage pharmaceutical research and development company that has developed a proprietary, patented polymer technology platform for drug development based upon polyoxazoline (POZ™), announced today that Dr. Randall Moreadith, President and CEO, will be speaking at the BIO CEO and Investor Conference at the Waldorf Astoria in New York during their annual meeting February 13-14th, 2017.

“I am delighted to participate in such a prestigious meeting of fellow CEOs,” said Dr. Moreadith. “This meeting brings together the most promising public and private companies in a setting where the top tier venture capital and investment bank teams have an opportunity to shape the future of biotechnology investments. I look forward to sharing Serina’s emerging portfolio of clinical and preclinical programs.”

SER-214, a once-per-week subcutaneous administration of rotigotine delivered in a standard insulin syringe, is currently being studied in a Phase 1 program in patients suffering from Parkinson’s disease. “SER-214 is designed to deliver therapeutic levels of rotigotine over the entire dosing period following a single weekly injection. This approach provides continuous dopaminergic tone and prevents the phasic peak and trough of many oral dopamine-like drugs that lead to the disabling dyskinesia eventually experienced by many patients.” said Dr. Moreadith. “We believe that SER-214 will not only become an important therapeutic in the treatment of Parkinson’s disease allowing patients to enjoy a better quality of life, but will also demonstrate the power of the POZ platform in addressing unmet medical need through programmed small molecule drug delivery.” SER-214 is completing the final multi-dose cohort now with plans to present those study results at an upcoming meeting in 2017.

In 2016 Serina introduced three new pipeline small molecule programs based on the POZ platform. SER-226 is an injectable POZ-conjugate of buprenorphine that is being developed for treatment of post-operative pain. The target product profile of SER-226 is 5-7 days of analgesia thus obviating the need for patients to transition to an oral pain drug – which is commonly an oral opiate. There is no current injectable drug candidate that provides such an extended profile. SER-226 has undergone initial proof-of-concept in animal models of pain and will enter IND-enabling studies in the second half of 2017.

SER-228 is a POZ-conjugate of cannabidiol (CBD), the major non-psychoactive component of Cannabis. SER-228 is a once-weekly injectable for the treatment of refractory epilepsy – a significant and unmet medical need worldwide. It is estimated that over 1 million adults and children in the US have refractory epilepsy, and as many as 20 million suffer from this worldwide. SER-228 may address this unmet need as a single weekly injectable that delivers cannabidiol continuously – an approach that is not currently available with oral drugs. SER-228 has undergone initial proof-of-concept studies in animals and will enter IND-enabling studies in the second half of 2017.
SER-232 is a POZ-conjugate of tetrahydrocannabinol (THC), the major psychoactive component of *Cannabis*. SER-232 is being developed for a host of medical needs including chemotherapy-induced nausea and vomiting (CINV), neuropathic pain, weight loss in AIDS and cancer, spasticity in multiple sclerosis and a number of other indications.

The use of CBD and THC as derivatives of *Cannabis* has shown promise in treatment of human disorders for decades, but these compounds may be limited by lack of a pure pharmaceutical preparation, poor solubility, low bioavailability and high first pass metabolism by the liver. Serina’s POZ technology allows for continuous drug delivery of the released drug following a single weekly injection, thus bypassing the poor bioavailability and high first pass metabolism of these promising drugs.

In addition to advancing its pipeline programs in pain, oncology, refractory seizures and CINV, Serina is currently collaborating with leading pharmaceutical companies to further unlock the promise of the POZ platform.

**About Serina**

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that has developed novel polymer therapeutics based on its proprietary polyoxazoline (POZ™) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled thirteen approved polyethylene glycol (PEG) products for various pharmaceutical partners. POZ technology provides strong differential characteristics that may demonstrate improved clinical benefits versus PEG and other polymer-based technologies. Besides developing its own pipeline of pharmaceutical products for Parkinson’s disease, pain, refractory epilepsy and cancer, Serina has partnered its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit www.serinatherapeutics.com.